ospemifene brand names osphena senshio produced shionogi oral medication indicated treatment dyspareunia pain sexual intercourse encountered women often postmenopausal ospemifene selective estrogen receptor modulator acting similarly estrogen vaginal epithelium building vaginal wall thickness turn reduces pain associated dyspareunia dyspareunia commonly caused vulvar vaginal medication approved fda february european commission marketing eu january ospemifene used treat dyspareunia us indicated treatment moderate severe dyspareunia symptom vulvar vaginal atrophy vva due menopause eu indicated treatment moderate severe symptomatic vva postmenopausal women candidates local vaginal oestrogen therapy women undiagnosed abnormal genital bleeding known suspected estrogendependent neoplasia active history deep vein thrombosis pulmonary embolism arterial thromboembolic disease may become pregnant known suspected breast cancer extreme hepatic impairment take full list contraindications side effects associated ospemifene include vaginal discharge hot flashes serious adverse effects similar estrogens estrogen receptor modulators include limited thromboembolism allergic reactions fatigue headache others could additional adverse effects ospemifene selective estrogen receptor modulator many effects produced estrogens produced ospemifene boxed warning medication indicates ospemifene may thicken endometrium could lead unusual bleeding endometrial cancer women taking estrogens concurrently taking type drug called progestin shown decrease occurrence endometrial theory progestins may expected attenuate ospemifenes effects endometrial thickening however clinical trials confirming conducted like estrogens ospemifene also may increase risk cardiovascular events including stroke coronary heart disease venous thromboembolism risk thrombotic hemorrhagic strokes given per women deep vein thrombosis estimated per women risks adverse events women taking ospemifene lower women taking estrogen alone form oral conjugated estrogens studies documented relative risk compared women taking estrogenprogestin therapy ospemifene estrogen agonistantagonist makes vaginal tissue thicker less fragile resulting reduction amount pain women experience sexual medication used shortest amount time possible due associated adverse ospemifene might adverse influence coagulation contrast estrogens serms like tamoxifen binding assay also performed measure affinity ospemifene estrogen receptor erα study showed ospemifene bound erα erβ similar ospemifene bound estrogen receptors lower affinity ospemifene shown antagonist eremediated transactivation cells authors concluded indicates antiestrogenic activity breast cancer pharmacokinetics ospemifene dosedependent dose range hormos medical ltd part quatrx pharmaceuticals filed patent january solid dosage form march quatrx pharmaceuticals licensed ospemifene shionogi co ltd clinical development new drug application nda submitted fda april amendments nda submitted june july august october november january february ultimately approved fda february ospemifene brand name senshio subsequently approved european commission marketing eu january preclinical trials performed ovariectomized rats model oral ospemifene compared raloxifene another serm metabolites ospemifene ospemifene estradiol ospemifene administered intravaginal estradiol used positive control raloxifene used drug class multiple doses oral ospemifene mgkgday ospemifene found cause greater increase vaginal weight vaginal epithelial height mgkgday vaginal weight increase twoweek treatment mgkgday number progesterone receptors increased vaginal stroma epithelium indicates ospemifene estrogenic two phase clinical trials performed one evaluated effects ospemifene vaginal tissue thickness composition vaginal ph evaluated effects ospemifene vaginal tissue symptoms dyspareunia two trials signs symptoms measured included three tissuerelated signs two represented histological changes vaginal tissue change percent parabasal cells change percent superficial cells third change vaginal ph dyspareunia evaluated one trials defined change bothersome symptom discomfort sexual activity limited symptoms either vaginal dryness vaginal ospemifene produced changes vaginal tissue greater reduction dyspareunia symptoms doseresponse also observed trial ospemifene mg greater efficacy ospemifene safety also evaluated phase trials increase incidence hot flushes increase urinary tract infections increase incidence headache ospemifene one phase trials randomized doubleblind placebocontrolled trial postmenopausal trial patients required one symptom vulvovaginal atrophy vva moderate severe nature fewer cells superficial examined vaginal smear vaginal ph least trial quantify relief dyspareunia study outcome measure phase trial conducted women aged diagnosed vva whose worst symptom first half fiscal year osphena generated b yen revenue probably roughly equivalent us osphena put onto market predicted earn million httpsenwikipediaorgwikiospemifene